MRNA—The Road to Reshaping the mRNA Technology Empire in the Post-Pandemic Era

Moderna's stock price experienced a challenging journey in 2026, from peak to trough and then to rediscovering its direction. When the extraordinary revenue from COVID-19 vaccines became a thing of the past, whether MRNA could reshape its growth trajectory through its mRNA technology platform is a core question every investor watching this stock must answer.

After losing the massive income from COVID-19 vaccines, Moderna's financial data in 2025 saw a significant pullback, with revenue dropping sharply from previous highs, and the company temporarily falling into losses. This is the fundamental reason for the continued pressure on MRNA's stock price. However, the market's pessimistic narrative may have been exaggerated. A careful breakdown of Moderna's current pipeline layout reveals a clear path to growth recovery.

The respiratory syncytial virus (RSV) vaccine is the first major product to take the baton. Moderna's RSV vaccine has received approval for market launch in key markets, and its promotion among the elderly is steadily advancing. The sales peak of this product is expected to reach several billion dollars, at least partially filling the gap left by declining COVID-19 revenue. The combination vaccine with the flu shot is also in late-stage clinical trials; if successful and approved, it will significantly enhance the company's competitive position in the seasonal respiratory vaccine market.

More long-term potential lies in the field of cancer treatment. Moderna's personalized cancer vaccine, developed in partnership with Merck, has shown promising results in melanoma clinical data, significantly reducing the risk of postoperative recurrence. If this technological approach can be expanded to more solid tumor types, its market space will far surpass that of preventive vaccines. The application of mRNA technology in tumor neoantigen therapies represents a paradigm-shifting treatment innovation. Of course, commercialization still requires time; the speed of clinical trial progress and final data are critical to success or failure.

Rare diseases and latent viral infections are also areas Moderna is exploring. These fields face relatively less competition and have strong pricing power. Breakthroughs here could open new profit growth points for the company. From the company's balance sheet perspective, Moderna accumulated substantial cash reserves during the COVID period, providing ample resources for pipeline R&D and potential strategic acquisitions—an advantage that is rare in the biotech industry.

On the technical front, after rebounding from last year's historical lows, MRNA's stock price remains relatively low. On the daily chart, the price is trading below the 200-day moving average, and the overall trend has not yet reversed. However, bottom-volume accumulation is evident, and downward momentum is gradually weakening. For investors optimistic about the long-term prospects of mRNA technology, the current price zone may offer a window to gradually build observation positions. But it is important to recognize that the high uncertainty characteristic of biotech stocks has not changed, and position management must match risk tolerance. How do you evaluate Moderna's transition from a vaccine company to a technology platform company? Feel free to share your independent thoughts.